[go: up one dir, main page]

TW200621728A - Pyrimidine derivatives - Google Patents

Pyrimidine derivatives

Info

Publication number
TW200621728A
TW200621728A TW094129174A TW94129174A TW200621728A TW 200621728 A TW200621728 A TW 200621728A TW 094129174 A TW094129174 A TW 094129174A TW 94129174 A TW94129174 A TW 94129174A TW 200621728 A TW200621728 A TW 200621728A
Authority
TW
Taiwan
Prior art keywords
pyrimidine derivatives
derivatives
pharmaceuticals
novel
processes
Prior art date
Application number
TW094129174A
Other languages
English (en)
Inventor
Eiji Kawahara
Takahiro Miyake
Johannes Roesel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200621728A publication Critical patent/TW200621728A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW094129174A 2004-08-27 2005-08-26 Pyrimidine derivatives TW200621728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0419160.7A GB0419160D0 (en) 2004-08-27 2004-08-27 Organic compounds

Publications (1)

Publication Number Publication Date
TW200621728A true TW200621728A (en) 2006-07-01

Family

ID=33104745

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094129174A TW200621728A (en) 2004-08-27 2005-08-26 Pyrimidine derivatives

Country Status (24)

Country Link
US (1) US7910585B2 (zh)
EP (1) EP1784399B1 (zh)
JP (1) JP4674236B2 (zh)
KR (1) KR100894349B1 (zh)
CN (1) CN101006079A (zh)
AR (1) AR050536A1 (zh)
AT (1) ATE512960T1 (zh)
AU (1) AU2005276585B2 (zh)
BR (1) BRPI0514731A (zh)
CA (1) CA2575720C (zh)
EC (1) ECSP077259A (zh)
ES (1) ES2366038T3 (zh)
GB (1) GB0419160D0 (zh)
GT (1) GT200500229A (zh)
IL (1) IL181386A0 (zh)
MA (1) MA28813B1 (zh)
NO (1) NO20071504L (zh)
PE (1) PE20060504A1 (zh)
PL (1) PL1784399T3 (zh)
PT (1) PT1784399E (zh)
RU (1) RU2395507C2 (zh)
TN (1) TNSN07074A1 (zh)
TW (1) TW200621728A (zh)
WO (1) WO2006021457A2 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP2447359B1 (en) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
TWI432427B (zh) * 2006-10-23 2014-04-01 Cephalon Inc 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物
HRP20141260T1 (xx) 2006-12-08 2015-03-13 Irm Llc Spojevi i sastavi kao inhibitori kinaze proteina
WO2008076243A2 (en) * 2006-12-14 2008-06-26 Merck & Co., Inc. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
WO2009153589A1 (en) 2008-06-17 2009-12-23 Astrazeneca Ab Pyridine compounds
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074210A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN101935317B (zh) * 2009-07-01 2013-08-28 上海药明康德新药开发有限公司 2-甲基-7-(取代嘧啶-4-氨基)-4-(取代哌啶-1-基)异吲哚啉-1-酮及中间体的合成方法
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) * 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6108570B2 (ja) 2013-02-13 2017-04-05 学校法人福岡大学 迅速アレルギー検査方法
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2,4,5‑三取代嘧啶类化合物及其制备方法和用途
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
WO2021050964A1 (en) * 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6776480B2 (en) 2001-07-18 2004-08-17 Sola International Holdings, Ltd. Spectacle frames for shaped lenses defined by monoformal carrier surfaces
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7910585B2 (en) 2011-03-22
CN101006079A (zh) 2007-07-25
EP1784399A2 (en) 2007-05-16
US20080293708A1 (en) 2008-11-27
GT200500229A (es) 2006-03-29
PE20060504A1 (es) 2006-07-18
AU2005276585B2 (en) 2009-07-30
PL1784399T3 (pl) 2011-11-30
CA2575720A1 (en) 2006-03-02
ECSP077259A (es) 2007-03-29
RU2007110946A (ru) 2008-10-10
BRPI0514731A (pt) 2008-06-24
KR100894349B1 (ko) 2009-04-22
AU2005276585A1 (en) 2006-03-02
WO2006021457A2 (en) 2006-03-02
ATE512960T1 (de) 2011-07-15
JP2008510765A (ja) 2008-04-10
NO20071504L (no) 2007-05-25
EP1784399B1 (en) 2011-06-15
JP4674236B2 (ja) 2011-04-20
RU2395507C2 (ru) 2010-07-27
CA2575720C (en) 2012-10-02
IL181386A0 (en) 2007-07-04
ES2366038T3 (es) 2011-10-14
TNSN07074A1 (en) 2008-06-02
GB0419160D0 (en) 2004-09-29
WO2006021457A3 (en) 2006-07-13
PT1784399E (pt) 2011-08-26
MA28813B1 (fr) 2007-08-01
AR050536A1 (es) 2006-11-01
KR20070038567A (ko) 2007-04-10

Similar Documents

Publication Publication Date Title
TW200621729A (en) Pyrimidine derivatives
TNSN07074A1 (en) Pyrimidine derivatives
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TW200732323A (en) Organic compounds
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
TW200611904A (en) Aza-bicyclononanes
TN2011000245A1 (en) Organic compounds
TNSN05225A1 (en) 2,4-di(phenylamino) pyrimidines useful in the treatment of neoplastic diseases inflammatory and immune system disorders
GEP20146125B (en) Aminopyrimidines as syk inhibitors
TN2011000244A1 (en) Organic compounds
MX2011005934A (es) Compuestos organicos.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
DE602004024213D1 (en) Aminopropanolderivate
JO2734B1 (en) Organic compounds
GB0508318D0 (en) Organic compounds
TW200716568A (en) 1H-quinazoline-2,4-diones
MX2007008237A (es) Compuestos de piridina novedosos.
WO2006010591A3 (en) Quinazoline derivatives
PL1877367T3 (pl) Pochodne acetylenu
TW200628153A (en) Novel compounds
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
GB0525069D0 (en) Organic compounds
MX2009005182A (es) Derivados de 2-hidroxi-1,3-diamino-propano.